Addressing poverty-related diseases with sustainable
and paradigm-shifting innovations.
Get in touch
Landcent is currently raising funds complete the final phase R&D and semi-field trials of our next-generation malaria prevention technologies. Our investors will contribute to unlocking $4 trillion of economic potential.
Landcent is raising funds for the final product certification and qualification, towards market entry in 2025.
The World Health Organization (WHO) African Region is our target market. Once our products are qualified by the WHO, customers such as The Global Fund, President's Malaria Initiative, UNICEF, World Vision etc. purchase the products from us for distribution across Africa.
There is a market of €855M for our 3 vector control tools - LLINs, IRS, and Anti-malarial Pills. Our emerging solutions (repellents, larvicides) & active ingredients for vector control would significantly expand this market size.
This round of funding is an all equity raise
This final round of funding closes Q4, 2023